Pipeline Overview
Our pipeline leverages the deterministic Moleculogic engine to generate traceable, programmable drug blueprints. All compounds are logic-verified, entropy-stabilized, and regulation-aware before clinical development.
Moleculogic Advantage
Logic is the Drug. Simulation is the Proof. All molecules are generated by Moleculogic's deterministic engine with no random screening or guesswork.
Metal Drug Complex (MDC) Pipeline
| Compound Name | Indication | Mechanism | Status |
|---|---|---|---|
| Ru⁴⁺-Doxorubicin | Oncology | TME-pH-triggered release | Tier 2 - Preclinical |
| Zn²⁺-Ivermectin | Antiviral | Metal-enhanced viral disruption | Tier 2 - IND-Enabling |
| Cu²⁺-Histidine | Neuroinflammation | ROS-gated metal delivery | Tier 1 - Simulated |
| Pt²⁺-GRX-REGEN-χ1 | Hair Graying Reversal | McSC redox modulation | Tier 2 - Validated |
| Fe²⁺-20e-Ferrocene-X | Redox Cancer Therapy | 20-electron redox overload | Tier 1 - Simulation |
| AIM001-MDC-χ2 | Immuno-oncology (MITF+) | Tumor-restricted ROS tuning | Tier 2 - Simulated |
| QRX-HX1-MDC | Renal Fibrosis | Redox-NAD anti-fibrotic triad | Tier 1 - Prototype |
Pt²⁺-GRX-REGEN-χ1
A Tier 2 molecule derived from the GRX-REGEN-χ1 logic blueprint, targeting human hair graying reversal. It exploits redox triggers in melanocyte stem cells to reinitiate pigmentation through MITF and NAD⁺ cycling pathways.
Functional Drug Complex (FDC) Pipeline
| Complex Name | Indication | Mechanism | Status |
|---|---|---|---|
| Peptide-RNA ImmunoMod | Autoimmune | RNA-guided immune tuning | Tier 2 - Concept Verified |
| OncoLogic-FDC | Oncology | Glyco-tagged nanoshell logic | Tier 2 - Preclinical |
| FDC-AIM-χ1 | Autoimmune (IL-2Rα) | Treg selective activation | Tier 2 - Simulated |
| FDC-AIM-χ2 | Autoimmune + Muscle | Thermogenesis + Tolerance | Tier 1 - Simulation |
| FDC-TREGBAL-χ1 | Treg Therapy | IL-2 mutein replacement | Tier 1 - Simulation |
| FDC-REGEN-χ2 | Hair Graying | Dual NAD/Stem niche logic | Tier 1 - Simulated |
| Redunera | CKD (T2D/HTN) | Entropy-stabilized renal therapy | Tier 4 - Simulation Verified |
| QRX-HX1-FDC | Renal Fibrosis | Ubiquinone/NAC/ATP modulation | Tier 1 - Early Simulation |
FDC-AIM-χ1
A Moleculogic Tier 2 blueprint that offers an IL-2Rα-selective immunologic rebalance strategy without systemic T cell activation. Includes entropy overlays for Foxp3, redox buffering, and Treg bias.
Redunera
Redunera is a Tier 4 logic-enhanced therapeutic blueprint engineered for chronic kidney disease (CKD) patients with Type 2 Diabetes and Hypertension. It builds upon the QRX-3 backbone with layered entropy stabilization, renal-targeted delivery, and immune feedback suppression.
Development Timeline
2025 Q1-Q2
GRX-REGEN-χ1 in vitro completed; QRX-HX1 preclinical modeling initiated; Tier 4 full simulation of Redunera logic stack completed.
2025 Q3
IND-enabling data package for Ru⁴⁺-Doxorubicin and FDC-AIM-χ1; Partner readiness evaluation for renal trials in Type 2 diabetic CKD.
2025 Q4
Phase I preparation for lead MDC/FDC combo trials (dual path); Redunera partner-facing clinical logic sandbox preparation.
2026 H1
Aim: First Moleculogic IND filed; Tier 3 sandbox partners onboarded.
Partner with MetalDrug
Moleculogic compounds are logic-verified, entropy-stabilized, and regulation-aware. We welcome clinical development partners, biotech acquirers, and licensing inquiries for both early- and late-stage blueprints.